Literature DB >> 10024915

Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease.

A L Kelly1, D A Rhodes, J M Roland, P Schofield, T M Cox.   

Abstract

Juvenile haemochromatosis is a rare inborn error of iron metabolism with clinical manifestations before 30 years of age. Unlike adult haemochromatosis which principally affects men, juvenile haemochromatosis affects the sexes equally; it causes early endocrine failure, dilated cardiomyopathy and joint disease. We report four patients (two of each sex) from three pedigrees affected by juvenile haemochromatosis with a mean onset at 22 years (range 14-30). All had endocrine deficiency with postpubertal gonadal failure secondary to pituitary disease; two suffered near-fatal cardiomyopathy with heart failure. Mean time to diagnosis from the first clinical signs of disease was 9.8 years (range 0.5-20) but general health and parameters of iron storage responded favourably to iron-depletion therapy. A 24-year-old man listed for heart transplantation because of cardiomyopathy [left ventricular (LV) ejection fraction 16%] responded to intravenous iron chelation with desferrioxamine combined with phlebotomy (ejection fraction 31%). A 27-year-old woman with subacute biventricular heart failure refractory to medication required orthotopic cardiac transplantation before the diagnosis was established (LV ejection fraction 25%). Genetic studies showed that these two patients with cardiomyopathy from unrelated families were heterozygous for the HFE 845G-->A (C282Y) mutation and wild-type at the H63D locus: complete sequencing of the intron-exon boundaries and entire coding sequence of the HFE gene failed to identify additional lesions. Two siblings in a pedigree without cardiomyopathy were wild-type at the HFE C282Y locus; although the brother harboured a single copy of the 187C-->G (H63D) allele, segregation analysis showed that in neither sibling was the iron-storage disease linked to MHC Class I markers on chromosome 6p. Juvenile haemochromatosis is thus a genetically heterogenous disorder distinct from the common adult variant.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10024915     DOI: 10.1093/qjmed/91.9.607

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  7 in total

Review 1.  Hepcidin: what every gastroenterologist should know.

Authors:  A P Walker; J Partridge; S K Srai; J S Dooley
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

2.  Classification and genetic features of neonatal haemochromatosis: a study of 27 affected pedigrees and molecular analysis of genes implicated in iron metabolism.

Authors:  A L Kelly; P W Lunt; F Rodrigues; P J Berry; D M Flynn; P J McKiernan; D A Kelly; G Mieli-Vergani; T M Cox
Journal:  J Med Genet       Date:  2001-09       Impact factor: 6.318

Review 3.  Is genetic screening for hemochromatosis worthwhile?

Authors:  Omer T Njajou; Behrooz Z Alizadeh; Cornelia M van Duijn
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

4.  Juvenile hemochromatosis locus maps to chromosome 1q.

Authors:  A Roetto; A Totaro; M Cazzola; M Cicilano; S Bosio; G D'Ascola; M Carella; L Zelante; A L Kelly; T M Cox; P Gasparini; C Camaschella
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

5.  Allele frequencies of hemojuvelin gene (HJV) I222N and G320V missense mutations in white and African American subjects from the general Alabama population.

Authors:  James C Barton; Charles A Rivers; Sandrine Niyongere; Sean B Bohannon; Ronald T Acton
Journal:  BMC Med Genet       Date:  2004-12-20       Impact factor: 2.103

6.  Magnetic resonance susceptibility-weighted imaging versus other imaging modalities in detecting splenic siderotic lesions.

Authors:  Chuanming Li; Daiquan Zhou; Jun Zhao; Xin Wang; Wei Mu; Jian Wang
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

7.  A late presentation of a fatal disease: juvenile hemochromatosis.

Authors:  Cynthia Cherfane; Pauline Lee; Leana Guerin; Kyle Brown
Journal:  Case Rep Med       Date:  2013-09-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.